• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙蛋白酶I在体外对α-突触核蛋白正常和病理形式的不同切割模式

Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.

作者信息

Mishizen-Eberz Amanda J, Guttmann Rodney P, Giasson Benoit I, Day George A, Hodara Roberto, Ischiropoulos Harry, Lee Virginia M-Y, Trojanowski John Q, Lynch David R

机构信息

Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

出版信息

J Neurochem. 2003 Aug;86(4):836-47. doi: 10.1046/j.1471-4159.2003.01878.x.

DOI:10.1046/j.1471-4159.2003.01878.x
PMID:12887682
Abstract

Parkinson's disease (PD) is characterized by fibrillary neuronal inclusions called Lewy bodies (LBs) consisting largely of alpha-synuclein (alpha-syn), the protein mutated in some patients with familial PD. The mechanisms of alpha-syn fibrillization and LB formation are unknown, but may involve aberrant degradation or turnover. We examined the ability of calpain I to cleave alpha-syn in vitro. Calpain I cleaved wild-type alpha-syn predominantly after amino acid 57 and within the non-amyloid component (NAC) region. In contrast, calpain I cleaved fibrillized alpha-syn primarily in the region of amino acid 120 to generate fragments like those that increase susceptibility to dopamine toxicity and oxidative stress. Further, while calpain I cleaved wild-type alpha-syn after amino acid 57, this did not occur in mutant A53T alpha-syn. This paucity of proteolysis could increase the stability of A53T alpha-syn, suggesting that calpain I might protect cells from forming LBs by specific cleavages of soluble wild-type alpha-syn. However, once alpha-syn has polymerized into fibrils, calpain I may contribute to toxicity of these forms of alpha-syn by cleaving at aberrant sites within the C-terminal region. Elucidating the role of calpain I in the proteolytic processing of alpha-syn in normal and diseased brains may clarify mechanisms of neurodegenerative alpha-synucleinopathies.

摘要

帕金森病(PD)的特征是存在称为路易小体(LBs)的纤维状神经元内含物,其主要由α-突触核蛋白(α-syn)组成,该蛋白在一些家族性PD患者中发生突变。α-突触核蛋白纤维化和路易小体形成的机制尚不清楚,但可能涉及异常降解或周转。我们在体外检测了钙蛋白酶I切割α-突触核蛋白的能力。钙蛋白酶I主要在氨基酸57之后以及非淀粉样成分(NAC)区域内切割野生型α-突触核蛋白。相比之下,钙蛋白酶I主要在氨基酸120区域切割纤维化的α-突触核蛋白,以产生增加对多巴胺毒性和氧化应激敏感性的片段。此外,虽然钙蛋白酶I在氨基酸57之后切割野生型α-突触核蛋白,但在突变型A53Tα-突触核蛋白中并未发生这种情况。这种蛋白水解的缺乏可能会增加A53Tα-突触核蛋白的稳定性,这表明钙蛋白酶I可能通过特异性切割可溶性野生型α-突触核蛋白来保护细胞不形成路易小体。然而,一旦α-突触核蛋白聚合成纤维,钙蛋白酶I可能通过在C末端区域内的异常位点切割而导致这些形式的α-突触核蛋白产生毒性。阐明钙蛋白酶I在正常和患病大脑中α-突触核蛋白蛋白水解加工中的作用,可能会阐明神经退行性α-突触核蛋白病的机制。

相似文献

1
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.钙蛋白酶I在体外对α-突触核蛋白正常和病理形式的不同切割模式
J Neurochem. 2003 Aug;86(4):836-47. doi: 10.1046/j.1471-4159.2003.01878.x.
2
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.钙蛋白酶对α-突触核蛋白的切割:在α-突触核蛋白纤维化和硝化形式降解中的潜在作用。
Biochemistry. 2005 May 31;44(21):7818-29. doi: 10.1021/bi047846q.
3
Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.由A53Tα-突触核蛋白突变引起的家族性帕金森病中α-突触核蛋白和tau蛋白的纤维化
Exp Neurol. 2004 Jun;187(2):279-88. doi: 10.1016/j.expneurol.2004.01.007.
4
Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.α-突触核蛋白的钙蛋白酶切割:将蛋白水解加工与疾病相关的聚集联系起来
Am J Pathol. 2007 May;170(5):1725-38. doi: 10.2353/ajpath.2007.061232.
5
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.由α-突触核蛋白以及与帕金森病相关的两种突变形式在体外形成的原纤维是典型的淀粉样蛋白。
Biochemistry. 2000 Mar 14;39(10):2552-63. doi: 10.1021/bi991447r.
6
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.携带与家族性帕金森病相关的丙氨酸-53→苏氨酸突变的人α-突触核蛋白在转基因小鼠中导致伴有α-突触核蛋白聚集的神经退行性疾病。
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73. doi: 10.1073/pnas.132197599.
7
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.设计α-突触核蛋白聚集和毒性抑制剂作为帕金森病及相关疾病新疗法的策略。
FASEB J. 2004 Aug;18(11):1315-7. doi: 10.1096/fj.03-1346fje. Epub 2004 Jun 4.
8
Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.协同作用 20S 蛋白酶体和家族性帕金森病突变加速α-突触核蛋白寡聚体的形成。
J Bioenerg Biomembr. 2010 Feb;42(1):85-95. doi: 10.1007/s10863-009-9258-y. Epub 2010 Feb 11.
9
Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.丙氨酸30突变为脯氨酸以及丙氨酸53突变为苏氨酸对与帕金森病相关的α-突触核蛋白的物理和形态学特性的影响。
FEBS Lett. 1998 Nov 27;440(1-2):67-70. doi: 10.1016/s0014-5793(98)01419-7.
10
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.在转基因小鼠模型中再现了α-突触核蛋白在人类路易体病中的选择性不溶性。
Am J Pathol. 2001 Dec;159(6):2215-25. doi: 10.1016/s0002-9440(10)63072-6.

引用本文的文献

1
Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation.α-突触核蛋白C末端截短在病理学及路易小体形成中的不同作用
NPJ Parkinsons Dis. 2025 Aug 26;11(1):261. doi: 10.1038/s41531-025-01084-y.
2
A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson's disease.在血清中定量的钙蛋白酶-1切割的α-突触核蛋白片段在帕金森病患者中上调。
Sci Rep. 2025 Apr 9;15(1):12081. doi: 10.1038/s41598-025-92726-x.
3
SENP2-based N-terminal truncation of α-synuclein in Lewy pathology propagation.
基于SENP2的α-突触核蛋白N端截短在路易体病理传播中的作用
iScience. 2025 Jan 31;28(2):111935. doi: 10.1016/j.isci.2025.111935. eCollection 2025 Feb 21.
4
Accumulation of alpha-synuclein pathology in the liver exhibits post-translational modifications associated with Parkinson's disease.肝脏中α-突触核蛋白病理的积累表现出与帕金森病相关的翻译后修饰。
iScience. 2024 Nov 23;27(12):111448. doi: 10.1016/j.isci.2024.111448. eCollection 2024 Dec 20.
5
α-Synuclein pathology as a target in neurodegenerative diseases.α-突触核蛋白病变作为神经退行性疾病的一个靶点。
Nat Rev Neurol. 2025 Jan;21(1):32-47. doi: 10.1038/s41582-024-01043-w. Epub 2024 Nov 28.
6
The small molecule ZPD-2 inhibits the aggregation and seeded polymerisation of C-terminally truncated α-Synuclein.小分子ZPD-2可抑制C端截短的α-突触核蛋白的聚集和种子聚合。
FEBS J. 2024 Dec;291(23):5290-5304. doi: 10.1111/febs.17310. Epub 2024 Oct 27.
7
Posttranslational Modifications of -Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases.- 突触核蛋白的翻译后修饰、它们的治疗潜力,以及在健康和神经退行性疾病中的相互作用。
Pharmacol Rev. 2024 Oct 16;76(6):1254-1290. doi: 10.1124/pharmrev.123.001111.
8
20S proteasome enhancers prevent cytotoxic tubulin polymerization-promoting protein induced α-synuclein aggregation.20S蛋白酶体增强剂可防止细胞毒性微管蛋白聚合促进蛋白诱导的α-突触核蛋白聚集。
iScience. 2024 Jun 4;27(7):110166. doi: 10.1016/j.isci.2024.110166. eCollection 2024 Jul 19.
9
O-GlcNAc forces an α-synuclein amyloid strain with notably diminished seeding and pathology.O-GlcNAc 迫使α-突触核蛋白形成具有明显降低的种子和病理特征的淀粉样纤维。
Nat Chem Biol. 2024 May;20(5):646-655. doi: 10.1038/s41589-024-01551-2. Epub 2024 Feb 12.
10
Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy.抑制蛋白质聚集和内质网应激作为α-突触核蛋白病的靶向治疗方法。
Pharmaceutics. 2023 Jul 30;15(8):2051. doi: 10.3390/pharmaceutics15082051.